The antithrombogenic and antimicrobial peripheral venous catheter that will minimize common midline catheter complications like catheter intraluminal occlusion, thrombus accumulation and microbial colonization on the catheter surface for a minimum of 30 days.

It can also be used with high-pressure injection for diagnostic studies.

Teleflex said the Arrow Midline with Chlorag+ard technology will allow caregivers to effectively and economically protect the catheter from potential costly complications.

Teleflex vascular access division general manager and president Jay White said: “Clinicians are faced with a multitude of vascular access challenges. Development of new technology to ensure the patient receives the safest, most effective IV therapy possible should drive all medical device manufacturers.

“We at Teleflex continue to promote the message of ‘The Right Line for the Right Patient at the Right Time.’and through this belief we continue to develop products that help clinicians to champion better care,”

Earlier this month, the firm also received FDA 510(k) clearance for its Arrow JACC with Chlorag+ard technology and TightTrack tunneler.

Arrow JACC with Chlorag+ard technology is a tunneled, small french size antithrombogenic and antimicrobial central venous catheter that will be used to treat patients throughout their course of therapy or illness.

Teleflex produces various solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care.